Vilin Bio Med Ltd
₹ 38.0
1.74%
02 Apr
- close price
About
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]
Key Points
- Market Cap ₹ 53.0 Cr.
- Current Price ₹ 38.0
- High / Low ₹ 38.4 / 19.0
- Stock P/E 212
- Book Value ₹ 16.6
- Dividend Yield 0.00 %
- ROCE 4.20 %
- ROE 0.96 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -2.28% over past five years.
- Company has a low return on equity of 3.34% over last 3 years.
- Company has high debtors of 156 days.
- Company's cost of borrowing seems high
- Working capital days have increased from 106 days to 195 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 16.62 | 11.54 | 11.21 | 12.31 | 15.80 | 14.81 | 19.98 | |
| 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 19.27 | |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 0.71 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 3.55% |
| 0.01 | 0.00 | 0.00 | 0.02 | 0.32 | 0.47 | 0.25 | |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.51 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.10 | 0.10 |
| Profit before tax | 0.20 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 0.35 |
| Tax % | 20.00% | 25.00% | 25.00% | 30.34% | 26.09% | 25.81% | |
| 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 0.25 | |
| EPS in Rs | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | 10% |
| TTM: | 58% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 94% |
| TTM: | 151% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 3% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.30 | 3.30 | 3.30 | 9.95 | 13.95 | 13.95 | 13.95 |
| Reserves | 3.94 | 4.06 | 4.10 | 0.73 | 8.89 | 9.11 | 9.27 |
| 4.53 | 5.52 | 5.30 | 4.93 | 6.83 | 2.57 | 0.46 | |
| 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.10 | 1.32 | |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.73 | 25.00 |
| 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 3.07 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.88 | 21.93 | |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.73 | 25.00 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -1.46 | -1.00 | 0.21 | -1.66 | -7.42 | 0.22 | |
| -0.02 | 0.00 | 0.00 | -0.03 | 0.32 | -1.11 | |
| 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.10 | |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0.00 | 1.77 | -5.99 |
| Free Cash Flow | -1.48 | -1.00 | 0.21 | -1.69 | -7.42 | -1.35 |
| CFO/OP | -156% | -112% | 29% | -43% | -888% | 37% |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 159.66 | 241.96 | 253.64 | 166.04 | 131.22 | 155.51 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125.41 | 119.50 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 37.67 |
| Cash Conversion Cycle | 166.31 | 292.03 | 321.13 | 150.28 | 201.91 | 237.35 |
| Working Capital Days | 110.91 | 204.32 | 211.64 | 45.07 | 76.23 | 195.44 |
| ROCE % | 4.87% | 4.30% | 17.17% | 4.51% | 4.20% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Total Electricity Units Purchased Units |
|
||||
| Number of Dosage Form Categories Number |
|||||
| Number of Major Delivery Channels Types |
|||||
| Number of Manufacturing Units Number |
|||||
| Electricity Consumption for Production Units per lakh production |
|||||
Requires Premium
Requires Premium
Documents
Announcements
-
General Updates
30 March 2026 - NSE granted in-principle listing approval on Mar 30, 2026 for 13,00,000 preferentially allotted shares (FV Rs10).
-
Trading Window
27 March 2026 - Trading window closed Apr 1, 2026 until 48 hours after audited results for year/half-year ended Mar 31, 2026.
-
Outcome of Board Meeting
4 March 2026 - Allotment of 1,300,000 shares at ₹26 each (₹3.38Cr) on March 4, 2026 to two non-promoters.
-
General Updates
23 February 2026 - NSE granted in-principle approval to issue 1,300,000 equity shares on preferential basis (Feb 23, 2026).
-
Outcome of Board Meeting
16 February 2026 - Board approved amalgamation of Chemgenix into Vilin; 1:1 swap; 96,90,000 shares allotted; 13,00,000 preferential.
Business Overview:[1][2]
VBML is an ISO-9001-2008 & GMP certified manufacturer of Pharmaceutical formulations' viz. Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non βeta-Lactam), Tablets & Capsules (βeta & Non βeta-Lactam), External Preparations, etc. It sells its products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders. Company does not sell products under any brand name